1. SREBP-1 inhibitor Betulin enhances the antitumor effect of Sorafenib on hepatocellular carcinoma via restricting cellular glycolytic activity
- Author
-
Zongwei Li, Fan Yin, Fan Feng, Lei Wang, Xiaoning Wang, and Yu Cao
- Subjects
Sorafenib ,Cancer Research ,Cell biology ,Carcinoma, Hepatocellular ,Immunology ,Transplantation, Heterologous ,Mice, Nude ,Biochemistry ,Article ,Cellular and Molecular Neuroscience ,chemistry.chemical_compound ,Mice ,Cell Movement ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Carcinoma ,Animals ,Humans ,lcsh:QH573-671 ,Transcription factor ,neoplasms ,Cell Proliferation ,Cancer ,Betulin ,lcsh:Cytology ,Liver Neoplasms ,Lipid metabolism ,Drug Synergism ,Hep G2 Cells ,medicine.disease ,Lipid Metabolism ,Prognosis ,Triterpenes ,digestive system diseases ,Sterol regulatory element-binding protein ,Transplantation ,Gene Expression Regulation, Neoplastic ,chemistry ,Hepatocellular carcinoma ,Cancer research ,lipids (amino acids, peptides, and proteins) ,Sterol Regulatory Element Binding Protein 1 ,Glycolysis ,medicine.drug - Abstract
Lipid metabolism that correlates tightly to the glucose metabolic regulation in malignant cells includes hepatocellular carcinoma (HCC) cells. The transcription factor Sterol Regulatory Element Binding Protein 1 (SREBP-1), a regulator of fatty acid synthesis, has been shown to pivotally regulate the proliferation and metastasis of HCC cells. However, the intrinsic mechanism by which SREBP-1 regulates the survival of HCC cells remains unclear. In this study, among HCC patients who had dismal responses to Sorafenib, a high SREBP-1 level was found in the tumors and correlated to poor survival. This observation suggested the negative role of SREBP-1 in clinical HCC prognosis. Our mechanistical studies reveal that the inhibition of SREBP-1 via its inhibitor Betulin suppresses cellular glucose metabolism. In addition to the reduced glycolytic activity, a thwarted metastatic potential was observed in HCC cells upon Betulin administration. Moreover, our data show that SREBP-1 inhibition facilitated the antitumor effects of Sorafenib on HCC cells and xenograft tumors.
- Published
- 2019
- Full Text
- View/download PDF